论文部分内容阅读
癌症患者血中免疫复合物(IC)可作为阻抑因子而降低患者的免疫机能。作者应用3.5%多乙烯乙二醇(PEG)沉淀法测定了72例胃癌患者血清IC,同时测定了癌胚抗原(CEA)、免疫抑制酸性蛋白(IAP)、植物血凝素(PHA)·纯蛋白衍生物(PPD)皮内反应、PHA·刀豆素A(Con A)淋巴细胞转化等免疫指标,以分析与IC水平之间的关系。正常人IC值为0.479±0.06,胃癌患者的IC值随病情进展逐步增高,Ⅱ期胃癌为0.525±0.074,Ⅲ期为0.563±0.115,Ⅳ期为0.569±0.111,复发性胃癌为0.609±0.095(P<0.01)。 58例患者测定了IgA、IgG、IgM,43例测定了
The immune complex (IC) in the blood of cancer patients can act as a repressor and reduce the patient’s immune function. The authors used a 3.5% poly ethylene glycol (PEG) precipitation method to measure serum IC in 72 patients with gastric cancer. Simultaneous determination of carcinoembryonic antigen (CEA), immunosuppressive acidic protein (IAP), phytohemagglutinin (PHA), and pure Intradermal reaction of protein derivatives (PPD), PHA, Con A lymphocyte transformation, and other immune indicators, to analyze the relationship between IC levels. The IC value of normal subjects was 0.479±0.06. The IC value of gastric cancer patients gradually increased with the progression of the disease. The stage II gastric cancer was 0.525±0.074, the stage III was 0.563±0.115, the stage IV was 0.569±0.111, and the recurrent gastric cancer was 0.609±0.095 ( P<0.01). IgA, IgG, and IgM were measured in 58 patients and 43 were measured.